Vmbook Online ordering

Senesco Technologies Inc

Senesco Technologies Inc is a clinical stage biopharmaceutical company that is focused on the development of novel therapeutics for the treatment of cancer and autoimmune diseases. The company's lead product candidate is SNS-101, which is a proprietary drug candidate that has been shown to selectively induce apoptosis, or programmed cell death, in cancer cells.

Senesco Technologies is a public company listed on the NASDAQ stock exchange in the USA, under the ticker symbol "SNES". As of my knowledge up to October 2021, the company has a market capitalization of around $13 million and has 52.88 million outstanding shares.

The company's research and development efforts are primarily focused on its proprietary technology platform called the "Gene Knockdown Technology", which is designed to selectively silence genes that are involved in the growth and survival of cancer cells. By selectively targeting these genes, the company hopes to develop therapies that are more effective and have fewer side effects than traditional chemotherapies.

Senesco Technologies is headquartered in New York, USA and its operations are primarily focused on research and development activities related to its drug candidates.

It is important to note that the stock market is dynamic and the information provided above may have changed and it is always a good idea to check the latest financial data and current stock price from a reliable financial news source or the NASDAQ website.